CMS Sets 2026 Medicare Premiums and Deductibles as Costs Rise and Policy Changes Take Effect

CMS Sets 2026 Medicare Premiums and Deductibles as Costs Rise and Policy Changes Take Effect

CMS Sets 2026 Medicare Premiums and Deductibles as Cost Pressures Mount and Regulatory Fixes Temper Increases The Centers for Medicare & Medicaid Services (CMS) has released the 2026 Medicare Parts A and B premiums, deductibles, and income-related adjustment amounts, outlining another year of steady cost increases across the program. While the updates reflect predictable inflationary … Read more

Vietnam Targets 2026 Rollout of Free Annual Health Checks and Expanded Insurance Coverage

Vietnam Targets 2026 Rollout of Free Annual Health Checks and Expanded Insurance Coverage

Doctors providing check-ups with a sign announcing free annual health checks and expanded insurance. Vietnam Sets Ambitious 2026 Plan for Free Annual Health Checks, Expanded Coverage, and System-Wide Reform Vietnam is preparing to deliver one of its most far-reaching public-health reforms in decades, a nationwide guarantee of one free annual health check or screening for … Read more

Spain Expands Newborn Screening Portfolio and Launches National Asbestos Injury Certification in Dual Public Health Overhaul

Spain Expands Newborn Screening Portfolio and Launches National Asbestos Injury Certification in Dual Public Health Overhaul

Spanish health official displays a Ministry of Health certificate for asbestos-related injury, as Spain rolls out its new national certification system alongside expanded neonatal screening reforms. (Editorial illustration.) CISNS approves sweeping updates to neonatal diagnostics and formalizes a nationwide system to certify asbestos-related disease for compensation Spain’s Interterritorial Council of the National Health System (CISNS) … Read more

TLV Endorses Keytruda Combo for Advanced Cervical Cancer with Cost-Effectiveness Caveats

TLV Endorses Keytruda Combo for Advanced Cervical Cancer with Cost-Effectiveness Caveats

Sweden’s TLV has published its health economic assessment of Merck’s Keytruda for locally advanced cervical cancer, finding clear efficacy benefits when added to chemoradiation. However, the agency warns that cost-effectiveness hinges on price transparency and real-world survival durability.